MCID: FBR017
MIFTS: 61

Fibrosarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Fibrosarcoma

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 12 77 54 60 30 56 45 15 17 74
Neoplasms, Fibrous Tissue 45 74
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

60
fibrosarcoma
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 60  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 69 53654007
MESH via Orphanet 46 D005354
ICD10 via Orphanet 35 C49.9
UMLS via Orphanet 75 C0016057
Orphanet 60 ORPHA2030

Summaries for Fibrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to congenital fibrosarcoma and pediatric fibrosarcoma. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Tamoxifen and Bone Density Conservation Agents have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and t cells, and related phenotypes are shRNA abundance <= 50% and growth/size/body region

Wikipedia : 77 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 congenital fibrosarcoma 34.1 ACTC1 ETV6 NTRK3
2 pediatric fibrosarcoma 33.3 ETV6 NTRK3
3 fasciitis 30.6 ACTC1 ETV6 TNF
4 breast adenocarcinoma 30.4 MMP2 MMP9 PLAU TNF
5 calcifying aponeurotic fibroma 30.2 ACTC1 FN1
6 cellular congenital mesoblastic nephroma 30.1 ETV6 NTRK3
7 joint disorders 30.1 PLAU TIMP1 TNF
8 aortic aneurysm, familial abdominal, 1 29.9 MMP2 MMP9 PLAU TIMP1 TIMP2
9 breast cancer 29.1 MALAT1 MMP14 MMP2 MMP9 NTRK3 PLAU
10 small bowel fibrosarcoma 12.3
11 liver fibrosarcoma 12.3
12 kidney fibrosarcoma 12.3
13 heart fibrosarcoma 12.3
14 breast fibrosarcoma 12.2
15 fibrosarcoma of bone 12.2
16 adult fibrosarcoma 12.2
17 central nervous system fibrosarcoma 12.2
18 conventional fibrosarcoma 12.1
19 dermatofibrosarcoma protuberans 11.6
20 fibroma 11.5
21 infantile myofibromatosis 11.4
22 desmoid tumor 11.4
23 inflammatory myofibroblastic tumor 11.4
24 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.4
25 chromosome 17q11.2 deletion syndrome 11.1
26 extracranial arteriovenous malformation 10.5 MMP2 MMP9
27 adult mesoblastic nephroma 10.5 ETV6 NTRK3
28 focal myositis 10.5 MMP2 MMP9
29 amaurosis fugax 10.5 MMP9 SERPINE1
30 spastic entropion 10.5 MMP2 MMP9
31 lentigo maligna melanoma 10.5 MMP2 MMP9
32 ischemic colitis 10.5 MMP2 MMP9 SERPINE1
33 conjunctival nevus 10.5 MMP2 MMP9 TIMP1
34 multicentric osteolysis, nodulosis, and arthropathy 10.5 MMP14 MMP2
35 maxillary cancer 10.4 MMP2 PLAU TIMP1
36 psammomatous meningioma 10.4 MMP2 MMP9
37 chronic venous insufficiency 10.4 MMP9 SERPINE1 TIMP1
38 venous insufficiency 10.4 MMP9 SERPINE1 TIMP1
39 sarcoma 10.4
40 winchester syndrome 10.4 MMP14 MMP2
41 acute transverse myelitis 10.4 MMP2 MMP9
42 monoclonal gammopathy of uncertain significance 10.4 MAF MAFB TNF
43 villous adenocarcinoma 10.4 FN1 MMP2 MMP9
44 autoimmune inner ear disease 10.4 MMP9 TIMP1 TNF
45 fungal keratitis 10.4 MMP9 TIMP1 TIMP2
46 inner ear disease 10.4 MMP9 TIMP1 TNF
47 microcystic meningioma 10.4 MMP2 TIMP1 TIMP2
48 transverse myelitis 10.4 MMP2 MMP9 TNF
49 senile ectropion 10.4 MMP2 MMP9
50 adenomyosis 10.4 MMP2 MMP9 TIMP2

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 ETV6 GPI MAF MAFB MAFF MAFG

MGI Mouse Phenotypes related to Fibrosarcoma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 ACTC1 ETV6 FN1 GPI MAF MAFA
2 cardiovascular system MP:0005385 10.38 ACTC1 ETV6 FN1 GPI MAFB MMP14
3 homeostasis/metabolism MP:0005376 10.35 ACTC1 ETV6 FN1 GPI MAF MAFA
4 immune system MP:0005387 10.33 ETV6 FN1 GPI MAF MAFB MAFG
5 hematopoietic system MP:0005397 10.31 ETV6 FN1 GPI MAFG MAFK MMP14
6 mortality/aging MP:0010768 10.31 ACTC1 ETV6 FN1 GPI MAF MAFB
7 behavior/neurological MP:0005386 10.25 MAF MAFB MAFG MAFK MMP14 MMP9
8 craniofacial MP:0005382 10.07 FN1 MAF MAFB MMP14 MMP2 PLAU
9 integument MP:0010771 10.03 ETV6 FN1 MAF MMP14 MMP9 PLAU
10 nervous system MP:0003631 10.03 FN1 MAF MAFB MAFG MAFK MMP14
11 muscle MP:0005369 10.02 ACTC1 FN1 MAFG MAFK MMP14 MMP2
12 neoplasm MP:0002006 9.92 ETV6 FN1 MMP2 MMP9 PLAU SERPINE1
13 normal MP:0002873 9.85 ACTC1 ETV6 FN1 MAFA MAFB MAFF
14 reproductive system MP:0005389 9.61 FN1 MAFB MAFK MMP14 MMP9 NTRK3
15 respiratory system MP:0005388 9.32 GPI MAFB MMP14 MMP2 MMP9 NTRK3

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
2 Bone Density Conservation Agents Phase 4,Phase 2,Phase 1
3 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
4 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1,Not Applicable
5 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
6 Selective Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
7 Estrogens Phase 4,Phase 2,Phase 1,Early Phase 1
8 Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
10 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Estrogen Receptor Antagonists Phase 4,Phase 2,Phase 1
13 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
14 Estrogen Antagonists Phase 4,Phase 2,Phase 1
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
16 Evening Primrose Phase 4
17 Hypolipidemic Agents Phase 4
18 Analgesics Phase 4,Phase 2,Phase 1,Not Applicable
19 Lipid Regulating Agents Phase 4
20 Dermatologic Agents Phase 4,Phase 3,Phase 2
21 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
23 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
24 Anesthetics, Local Phase 4,Phase 3,Phase 2
25
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
26
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
27
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
28
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
29
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
30
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
31
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
32
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
33
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
34
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
35
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
36
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
37
Triamcinolone Approved, Vet_approved Phase 3,Phase 1 124-94-7 31307
38
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
39
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
40
Sorafenib Approved, Investigational Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
41
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
42
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
43
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
44
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
45
Cyproheptadine Approved Phase 3 129-03-3 2913
46
Histamine Approved, Investigational Phase 3 51-45-6 774
47
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
49
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 282)
# Name Status NCT ID Phase Drugs
1 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
2 Retreatment of Recurrent Dupuytren's Contractures Completed NCT01498640 Phase 4
3 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex Completed NCT01450397 Phase 4
4 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb Completed NCT01265420 Phase 4
5 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
6 Trial Comparing Treatment Strategies in Dupuytren's Contracture Recruiting NCT03192020 Phase 4 Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]
7 Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Recruiting NCT03000114 Phase 4 XIAFLEX
8 Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture Recruiting NCT02476461 Phase 4 xiapex
9 Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Active, not recruiting NCT02647619 Phase 4 Xiapex
10 Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease Enrolling by invitation NCT03406338 Phase 4 Collagenase Clostridium Histolyticum
11 Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture Terminated NCT01226121 Phase 4
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
13 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
14 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
15 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
17 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
18 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
19 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
20 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
21 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
22 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
23 Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00533273 Phase 3
24 Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00528840 Phase 3
25 AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00528424 Phase 3
26 Collagenase in the Treatment of Dupuytrens Disease Completed NCT00260429 Phase 3
27 Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures Completed NCT01674634 Phase 3
28 Collagenase Option for Reduction of Dupuytren's Contracture in Japan Completed NCT01588353 Phase 3 Collagenase Clostridium Histolyticum
29 Administration of Two Injections for Multiple Dupuytren's Contractures Completed NCT01407068 Phase 3
30 Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex) Completed NCT01229436 Phase 3 Xiapex
31 Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing Completed NCT00931567 Phase 2, Phase 3
32 Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture Completed NCT00565019 Phase 3 Triamcinolone Acetonide
33 AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture Completed NCT00528606 Phase 3
34 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
35 Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease Completed NCT00014742 Phase 3 collagenase
36 Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Recruiting NCT03785964 Phase 3 Nirogacestat oral tablet;Placebo Oral Tablet
37 Ledderhose Disease: Radiotherapy or Not? Recruiting NCT03507010 Phase 3
38 Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's Recruiting NCT02725528 Phase 3 collagenase injection
39 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
40 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
41 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Active, not recruiting NCT02066181 Phase 3 Sorafenib Tosylate
42 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
43 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
44 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
45 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
46 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
47 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
48 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
49 MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas Terminated NCT00147108 Phase 3
50 Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease Withdrawn NCT01776892 Phase 3 Collegenase injection

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma 30

Anatomical Context for Fibrosarcoma

MalaCards organs/tissues related to Fibrosarcoma:

42
Bone, Breast, T Cells, Brain, Thyroid, Heart, Bone Marrow

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 2734)
# Title Authors Year
1
Refractory and metastatic infantile fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable response to crizotinib. ( 30709876 )
2019
2
Utilizing photosensitizing and radiosensitizing properties of TiO2-based mitoxantrone imprinted nanopolymer in killing fibrosarcoma and melanoma cells. ( 30738223 )
2019
3
Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment. ( 30755816 )
2019
4
Cervical congenital infantile fibrosarcoma: a case report. ( 30797242 )
2019
5
Primary sclerosing epithelioid fibrosarcoma of the kidney: Report of two additional cases with a clinicopathological and molecular cytogenetic study. ( 30825419 )
2019
6
Regulation of radiosensitivity by 4-methylumbelliferone via the suppression of interleukin-1 in fibrosarcoma cells. ( 30867797 )
2019
7
Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. ( 30877273 )
2019
8
Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma. ( 30901500 )
2019
9
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. ( 29553955 )
2018
10
Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome. ( 29459759 )
2018
11
Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. ( 29430000 )
2018
12
Solubilization of a Poorly Soluble B-Raf (Rapidly Accelerated Fibrosarcoma) Inhibitor: From Theory to Application. ( 28989016 )
2018
13
Oxygen microbubbles improve radiotherapy tumor control in a rat fibrosarcoma model - A preliminary study. ( 29630640 )
2018
14
Primary Renal Hybrid Low-grade Fibromyxoid Sarcoma-Sclerosing Epithelioid Fibrosarcoma: An Unusual Pediatric Case With EWSR1-CREB3L1 Fusion. ( 29426275 )
2018
15
CT and MRI Findings of Soft Tissue Adult Fibrosarcoma in Extremities. ( 29693010 )
2018
16
Caffeine induces metformin anticancer effect on fibrosarcoma in hamsters. ( 29762853 )
2018
17
Outcomes following surgical excision or surgical excision combined with adjunctive, hypofractionated radiotherapy in dogs with oral squamous cell carcinoma or fibrosarcoma. ( 29911943 )
2018
18
Juvenile Bronchopulmonary Fibrosarcoma. ( 29944599 )
2018
19
Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. ( 29250984 )
2018
20
Spinal Sclerosing Epithelioid Fibrosarcoma at the Cervicothoracic Junction. ( 29574223 )
2018
21
Development of Orally Applicable, Combinatorial Drug-Loaded Nanoparticles for the Treatment of Fibrosarcoma. ( 29339136 )
2018
22
Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model. ( 29936460 )
2018
23
Successful management of congenital/infantile fibrosarcoma presenting as large, non-healing buttock ulceration. ( 29630153 )
2018
24
Primary tumor or metastasis? Extremely rare fibrosarcoma of the left atrial appendage. ( 29784427 )
2018
25
Sclerosing Epithelioid Fibrosarcoma of the Coccyx: A Case Report and Review of Literature. ( 29872588 )
2018
26
Rhodocetin-I+I^ selectively breaks the endothelial barrier of the tumor vasculature in HT1080 fibrosarcoma and A431 epidermoid carcinoma tumor models. ( 29854288 )
2018
27
Recurrent fibrosarcoma of maxillary sinus involving the cranial base: A rare case. ( 29970723 )
2018
28
Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. ( 29863809 )
2018
29
Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone. ( 29908016 )
2018
30
Fibrosarcoma arising in the paranasal sinus: a clinicopathological and radiological analysis. ( 29658783 )
2018
31
Unusual Presentation of Fibrosarcoma in a Child. ( 29615178 )
2018
32
ADAMTS-1 disrupts HGF/c-MET signaling and HGF-stimulated cellular processes in fibrosarcoma. ( 29355494 )
2018
33
Descending thoracic aortic aneurysm revealing metastasis of a soft tissue fibrosarcoma: a case report and review of the literature. ( 30473763 )
2018
34
Translocation Renal Cell Carcinoma in a Child Previously Treated for Infantile Fibrosarcoma. ( 28478739 )
2018
35
Mitochondria-targeted antioxidant SkQ1 suppresses fibrosarcoma and rhabdomyosarcoma tumour cell growth. ( 29995559 )
2018
36
CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma. ( 30030558 )
2018
37
Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. ( 30093116 )
2018
38
Expanding the spectrum of translocations in sclerosing epitheloid fibrosarcoma: A new case with EWSR1-CREB3L3 fusion. ( 30136738 )
2018
39
Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. ( 30187231 )
2018
40
Evaluation of anticancer effects of cerium oxide nanoparticles on mouse fibrosarcoma cell line. ( 30187476 )
2018
41
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. ( 30216849 )
2018
42
Canine oral fibrosarcoma: Changes in prognosis over the last 30 years? ( 30340654 )
2018
43
Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells. ( 30355481 )
2018
44
Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2. ( 30362638 )
2018
45
Immunomodulatory Effects of Blood Transfusion on Tumor Size, Metastasis, and Survival in Experimental Fibrosarcoma. ( 30369743 )
2018
46
Characterizing the DNA damage response in fibrosarcoma stem cells by in-situ cell tracking. ( 30373428 )
2018
47
Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells. ( 30404018 )
2018
48
Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. ( 30443492 )
2018
49
The spectrum of cutaneous adverse events during Encorafenib and Binimetinib treatment in BRAF mutant advanced melanoma. ( 30468696 )
2018
50
1-(5-Bromo-2-hydroxy-4-methoxyphenyl)ethanone [SE1] Inhibits MMP-9 Expression by Regulating NF-κB and MAPKs Signaling Pathways in HT1080 Human Fibrosarcoma Cells. ( 30519264 )
2018

Variations for Fibrosarcoma

Cosmic variations for Fibrosarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM27895 GNAS bone,femur,osteosarcoma,fibroblastic c.602G>A p.R201H 20:58909366-58909366 0

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 FN1 MAFF MAFG MAFK PLAU SERPINE1
2
Show member pathways
12.6 FN1 MMP14 MMP2 MMP9 SERPINE1 TIMP1
3 12.15 ETV6 MAF MMP9 PLAU
4 12.13 FN1 MMP2 MMP9 PLAU TNF
5 12.09 MMP14 MMP2 MMP9 TNF
6
Show member pathways
11.95 FN1 MMP2 MMP9 TNF
7 11.91 MMP14 MMP2 MMP9 SERPINE1
8 11.84 FN1 MMP14 PLAU SERPINE1
9 11.83 MMP14 MMP9 TNF
10 11.82 FN1 MMP2 MMP9 TIMP1 TNF
11 11.78 FN1 MMP2 SERPINE1 TNF
12 11.71 MMP2 MMP9 TIMP1 TIMP2
13
Show member pathways
11.63 MMP14 MMP2 MMP9 TIMP1 TIMP2 TNF
14 11.59 MMP14 MMP2 MMP9
15
Show member pathways
11.56 MMP2 MMP9 TNF
16 11.52 MMP2 MMP9 PLAU TIMP1 TNF
17
Show member pathways
11.39 MMP2 MMP9 PLAU
18 11.34 FN1 MMP2 MMP9 PLAU TNF
19 11.24 MMP2 MMP9 PLAU
20 11.08 MAF MAFA MAFB MAFF MAFG MAFK
21 11.07 MMP9 TIMP1 TIMP2
22 11.01 FN1 MMP14 MMP2 MMP9 PLAU SERPINE1
23 10.91 FN1 NTRK3 TIMP1 TIMP2 TNF
24 10.72 PLAU SERPINE1

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 FN1 GPI MMP2 MMP9 PLAU SERPINE1
2 collagen-containing extracellular matrix GO:0062023 9.55 FN1 MMP2 MMP9 SERPINE1 TIMP2
3 platelet alpha granule lumen GO:0031093 9.43 FN1 SERPINE1 TIMP1
4 extracellular matrix GO:0031012 9.43 FN1 MMP14 MMP2 MMP9 TIMP1 TIMP2
5 extracellular space GO:0005615 9.36 ACTC1 FN1 GPI MMP14 MMP2 MMP9

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.95 GPI PLAU SERPINE1 TIMP1 TNF
2 angiogenesis GO:0001525 9.88 FN1 MMP14 MMP2 SERPINE1
3 positive regulation of cell migration GO:0030335 9.86 MMP14 MMP9 NTRK3 PLAU
4 extracellular matrix organization GO:0030198 9.84 FN1 MMP9 SERPINE1 TNF
5 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 ETV6 MAF MAFA MAFB MAFF MAFG
6 blood coagulation GO:0007596 9.8 MAFF MAFG MAFK PLAU
7 positive regulation of gene expression GO:0010628 9.8 ACTC1 FN1 MAF MAFG NTRK3 TNF
8 response to organic substance GO:0010033 9.77 TIMP1 TIMP2 TNF
9 cytokine-mediated signaling pathway GO:0019221 9.77 FN1 MMP2 MMP9 TIMP1 TNF
10 ephrin receptor signaling pathway GO:0048013 9.74 MMP2 MMP9 NTRK3
11 response to hormone GO:0009725 9.69 MMP14 TIMP1 TIMP2
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 MMP2 MMP9 TNF
13 collagen catabolic process GO:0030574 9.61 MMP14 MMP2 MMP9
14 lens fiber cell differentiation GO:0070306 9.58 MAF NTRK3
15 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.52 TIMP1 TIMP2
16 negative regulation of metallopeptidase activity GO:1905049 9.46 TIMP1 TIMP2
17 regulation of epidermal cell differentiation GO:0045604 9.4 MAFF MAFG
18 transcription by RNA polymerase II GO:0006366 9.26 MAF MAFF
19 endodermal cell differentiation GO:0035987 9.26 FN1 MMP14 MMP2 MMP9
20 extracellular matrix disassembly GO:0022617 9.02 MMP14 MMP2 MMP9 TIMP1 TIMP2

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.8 ETV6 MAF MAFA MAFB MAFF MAFG
2 sequence-specific DNA binding GO:0043565 9.7 ETV6 MAF MAFA MAFB MAFF MAFG
3 serine-type endopeptidase activity GO:0004252 9.62 MMP14 MMP2 MMP9 PLAU
4 metalloendopeptidase activity GO:0004222 9.58 MMP14 MMP2 MMP9
5 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.5 ETV6 MAF MAFA MAFB MAFF MAFG
6 metalloendopeptidase inhibitor activity GO:0008191 9.37 TIMP1 TIMP2
7 protease binding GO:0002020 9.02 FN1 SERPINE1 TIMP1 TIMP2 TNF

Sources for Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....